Founded in 1994, Genesis is a biotechnology company based in Auckland, New Zealand, with a history of development of therapeutics for the treatment of cancer and diseases of the immune system.
Genesis has established Solirna Biosciences Ltd to develop a novel single stranded gene silencing technology which acts through the RNAi mechanism.
Genesis' long-term value proposition lies in its commitment to innovation in research and development and commercialising novel sciences. We place high priority on establishing and cultivating productive collaborations with industry partners, thereby fast-tracking the product development process and sharing risks and rewards with partners.
Genesis is listed on the New Zealand and Australian Stock Exchanges (GEN).
